P-012. Efficacy and safety of Paritaprevir/Ritonavir + Ombitasvir ± Dasabuvir ± Ribavirin in chronic hepatitis C patients with chronic renal failure

INTRODUCTION: Chronic hepatitis C (CHC) is common in patients with chronic kidney disease who are on hemodialysis. Because sofosbuvir is eliminated mainly by kidney, sofosbuvir-based regimens are not recommended in patients with estimated glomerular filtration rate (eGFR) < 30 ml/dak/1,73 m(2). I...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Turk J Gastroenterol
Hlavní autoři: Güzelbulut, Fatih, Aslan, Ekrem, Saltürk, Ayça Gökçen Değirmenci, Bahadır, Özgür, Şahin, Halil, Kiyak, Mevlüt, Kanatsız, Emine, Keçeci, Mustafa
Médium: Artigo
Jazyk:Inglês
Vydáno: Turkish Society of Gastroenterology 2019
Témata:
AASLD - TASL CONNECT REGIONAL MEETING, March 15–16, 2019 - İstanbul, Turkey
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7021071/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5152/tjg.2019.18
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky